Immunoglobulin E specific for Timothy grass pollen allergens (Timothy grass sIgE)

Immunoglobulin E (IgE) specific for Timothy grass (Phleum pratense) pollen allergens is a key mediator in the pathogenesis of seasonal allergic rhinitis and asthma (Valenta et al., 2019, Nature Reviews Disease Primers). These antibodies are produced by B cells upon sensitization to grass pollen proteins, such as Phl p 1 and Phl p 5, and bind to high-affinity FcεRI receptors on the surface of mast cells and basophils (Galli & Tsai, 2012, Nature Medicine). Upon subsequent exposure to Timothy grass pollen, the allergens cross-link the surface-bound IgE, triggering the release of histamine, leukotrienes, and cytokines that cause allergic symptoms (Akdis & Akdis, 2014, Advances in Immunology). Therapeutic strategies targeting this pathway include the use of monoclonal antibodies like Omalizumab, which sequesters free IgE, and allergen-specific immunotherapy (AIT), which aims to desensitize the immune system (Durham & Shamji, 2023, Journal of Allergy and Clinical Immunology). AIT works by shifting the immune response toward a regulatory phenotype, increasing the production of 'blocking' IgG4 antibodies that compete with IgE for allergen binding (Shamji & Durham, 2017, Nature Reviews Immunology). Monitoring specific IgE levels is crucial for diagnosing grass pollen allergy and assessing the efficacy of treatment interventions (Canonica et al., 2013, World Allergy Organization Journal).

Other names

Phleum pratense-specific IgETimothy grass-specific IgEAnti-Phl p IgEGrass pollen-specific IgETimothy grass sIgE

Omalizumab acts as a monoclonal antibody that binds to the Fc region of circulating IgE, preventing its interaction with high-affinity IgE receptors (FcεRI) on mast cells and basophils, thereby inhibiting the release of inflammatory mediators (FDA Label: Xolair). Allergen immunotherapy (AIT), such as Timothy grass pollen extracts (e.g., Grazax), involves the repeated administration of allergens to induce peripheral T-cell tolerance and promote the production of allergen-specific IgG4 antibodies, which act as 'blocking antibodies' to prevent IgE-mediated activation (Shamji & Durham, 2017, Nature Reviews Immunology).